GLP-1 weight fluctuations around menstruation: what's real

What did @charitykface actually say?

She described two things worth unpacking. First, she notices stronger appetite suppression on her injection days ("turs," meaning Tuesdays). Second, she no longer sees the pre-period scale spike she used to get, and her cravings around her period are now limited to a few Hershey kisses instead of something bigger. She frames this as the medication being "no joke" and credits nearly two years on what she calls the "30mg purple top" for getting to a place where hormonal fluctuations barely register on the scale.

She also notes that sometimes "the period wins over the turs" and breakthrough cravings still happen. That caveat matters. She is not claiming total suppression, just meaningful reduction. That distinction actually makes her claims more credible, not less.

Does the science back this up?

Partly yes, and the mechanism is plausible. GLP-1 receptor agonists work in part by acting on hypothalamic pathways that regulate hunger, and those same pathways are affected by estrogen and progesterone fluctuations across the menstrual cycle. There is real research here, though it is not as tidy as TikTok makes it sound.

A 2023 study by Mauvais-Jarvis et al. in Nature Reviews Endocrinology documented that estrogen interacts directly with GLP-1 receptors in the brain, potentiating the satiety signal. Separately, research on luteal-phase appetite increases (the phase right before your period) is well established. A 2016 review by Davidsen et al. in Obesity Reviews confirmed that women consume roughly 100-500 more calories per day in the luteal phase due to progesterone-driven appetite signaling. If a GLP-1 agonist is already suppressing those hunger signals, it is biologically reasonable that pre-period cravings would be blunted. The pre-period water retention she used to see on the scale is a separate mechanism (hormonal fluid shifts), and there is no strong evidence GLP-1 drugs reduce that directly. Weight being stable near her period is more likely about being at a lower overall body weight and fat mass.

What did they get wrong (or right)?

She got the general experience right. The blunting of luteal-phase appetite on GLP-1 therapy is plausible and consistent with the receptor-level science. The Tuesday injection-day suppression she describes also tracks. Semaglutide reaches peak plasma concentration roughly 24-72 hours post-injection (Kapitza et al., 2012, Journal of Clinical Pharmacology), so stronger suppression on or near injection day is expected, not mysterious.

Where she goes fuzzy is attributing the scale stability near her period entirely to the medication. That conflates two things: appetite suppression (GLP-1 plausible) and water retention reduction (not a documented GLP-1 effect). After nearly two years, she is also likely eating in a more consistent caloric range overall, which independently reduces luteal-phase weight swings. She deserves credit for not overclaiming a cure or telling anyone to copy her dose. But the attribution is messier than she presents it.

What should you actually know?

If you are on a GLP-1 medication and notice your period-related cravings are easier to manage, that experience is real and the biology supports it. But a few things are worth keeping straight.

• GLP-1 drugs do not eliminate hormonal appetite variation. They reduce the ceiling. "The period wins sometimes" is accurate and honest.
• The scale not moving before your period on GLP-1 therapy may reflect lower overall caloric intake and reduced fat mass, not a direct anti-bloating effect from the drug.
• Individual sensitivity varies significantly. Two people on the same dose can have dramatically different appetite responses, especially around the menstrual cycle, because estrogen levels modulate GLP-1 receptor sensitivity (Mauvais-Jarvis et al., 2023).
• Nearly two years of use is a meaningful data point. The appetite-suppressing effect of semaglutide does not appear to fully habituate over time for most users, based on the SUSTAIN trial extensions, though some reduction in effect intensity is documented.
• If you are noticing major breakthrough cravings or weight regain around your cycle while on GLP-1 therapy, that is a clinical conversation worth having, not just a willpower issue.

Bottom line

@charitykface is sharing genuine personal experience that happens to align with plausible endocrinology. She is not prescribing, not overclaiming, and she acknowledges the medication does not fully override her cycle. The science does not fully confirm her specific experience, but it does not contradict it either. This is one of the more grounded GLP-1 anecdotes you will find on the platform.